A
Price
$176.91Alerts
Change
-$0.98 (-0.55%)
Updated
Nov 11, 04:59 PM (EDT)
Capitalization
49.27B
11 days until earnings call
Intraday BUY SELL Signals
APYX
Price
$3.00Alerts
Change
+$0.07 (+2.39%)
Updated
Nov 11 closing price
Capitalization
123.42M
126 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

A vs APYX

A vs APYX Comparison Chart in %
View a ticker or compare two or three
VS
A vs. APYX commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and APYX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for A with price predictions
Nov 11, 2026

Aroon Indicator for A shows an upward move is likely

A's Aroon Indicator triggered a bullish signal on November 06, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 209 similar instances where the Aroon Indicator showed a similar pattern. In 141 of the 209 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 67%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +4.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where A advanced for three days, in 187 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.

Bearish Trend Analysis

The 10-day RSI Indicator for A moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 19 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 68 cases where A's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 65%.

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on A as a result. In 56 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.

The Moving Average Convergence Divergence Histogram (MACD) for A turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 25 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where A declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.

A broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 11 (best 1 - 100 worst), indicating outstanding price growth. A’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.692) is normal, around the industry mean (67.298). P/E Ratio (34.334) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (1.447) is also within normal values, averaging (3.473). Dividend Yield (0.006) settles around the average of (0.002) among similar stocks. P/S Ratio (5.910) is also within normal values, averaging (9.775).

The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. A’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.

A.I.Advisor
a Summary for APYX with price predictions
Nov 11, 2026

APYX's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for APYX turned positive on October 12, 2026. Looking at past instances where APYX's MACD turned positive, the stock continued to rise in 41 of 45 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on APYX as a result. In 90 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

APYX moved above its 50-day moving average on November 05, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for APYX crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.

Following a +7.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where APYX advanced for three days, in 196 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The 10-day RSI Indicator for APYX moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 22 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 57 of 59 cases where APYX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where APYX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

APYX broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for APYX entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.575) is normal, around the industry mean (4.142). P/E Ratio (-14.650) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.390) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.196) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. APYX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APYX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
A vs APYX: Fundamental Ratings
A
APYX
OUTLOOK RATING
1..100
7932
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
19
Undervalued
PROFIT vs RISK RATING
1..100
67100
SMR RATING
1..100
4599
PRICE GROWTH RATING
1..100
1159
P/E GROWTH RATING
1..100
4415
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APYX's Valuation (19) in the Medical Specialties industry is in the same range as A (24) in the Biotechnology industry. This means that APYX’s stock grew similarly to A’s over the last 12 months.

A's Profit vs Risk Rating (67) in the Biotechnology industry is somewhat better than the same rating for APYX (100) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than APYX’s over the last 12 months.

A's SMR Rating (45) in the Biotechnology industry is somewhat better than the same rating for APYX (99) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than APYX’s over the last 12 months.

A's Price Growth Rating (11) in the Biotechnology industry is somewhat better than the same rating for APYX (59) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than APYX’s over the last 12 months.

APYX's P/E Growth Rating (15) in the Medical Specialties industry is in the same range as A (44) in the Biotechnology industry. This means that APYX’s stock grew similarly to A’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AAPYX
RSI
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
65%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
65%
Bullish Trend 1 day ago
85%
MACD
ODDS (%)
Bearish Trend 1 day ago
57%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
62%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
63%
Bullish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 3 days ago
62%
Bullish Trend 14 days ago
84%
Declines
ODDS (%)
Bearish Trend 1 day ago
63%
Bearish Trend 20 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
67%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
67%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (A: $176.95 vs. APYX: $2.93)
Brand notoriety: A and APYX are both not notable
A represents the Medical Specialties, while APYX is part of the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: A: 85% vs. APYX: 43%
Market capitalization -- A: $49.27B vs. APYX: $123.42M
A [@Medical Specialties] is valued at $49.27B. APYX’s [@Medical/Nursing Services] market capitalization is $123.42M. The market cap for tickers in the [@Medical Specialties] industry ranges from $27 to $4.39T. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $190.22B. The average market capitalization across the [@Medical Specialties] industry is $20.94B. The average market capitalization across the [@Medical/Nursing Services] industry is $6.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

A’s FA Score shows that 2 FA rating(s) are green while APYX’s FA Score has 2 green FA rating(s).

  • A’s FA Score: 2 green, 3 red.
  • APYX’s FA Score: 2 green, 3 red.
According to our system of comparison, A is a better buy in the long-term than APYX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

A’s TA Score shows that 2 TA indicator(s) are bullish while APYX’s TA Score has 5 bullish TA indicator(s).

  • A’s TA Score: 2 bullish, 6 bearish.
  • APYX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, APYX is a better buy in the short-term than A.

Price Growth

A (@Medical Specialties) experienced а -0.12% price change this week, while APYX (@Medical/Nursing Services) price change was +12.69% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.83%. For the same industry, the average monthly price growth was -5.05%, and the average quarterly price growth was +38.36%.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.

Reported Earning Dates

A is expected to report earnings on Nov 23, 2026.

APYX is expected to report earnings on Mar 18, 2027.

Industries' Descriptions

@Medical Specialties (-4.83% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

@Medical/Nursing Services (-2.89% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

A and

Correlation & Price change

A.I.dvisor indicates that over the last year, A has been closely correlated with TMO. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then TMO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To A
1D Price
Change %
A100%
-0.52%
TMO - A
73%
Closely correlated
-0.07%
BRKR - A
72%
Closely correlated
+0.27%
MTD - A
69%
Closely correlated
-0.14%
RGEN - A
67%
Closely correlated
-0.78%
WAT - A
67%
Closely correlated
-0.97%
More

APYX and

Correlation & Price change

A.I.dvisor tells us that APYX and SGHT have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APYX and SGHT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APYX
1D Price
Change %
APYX100%
+2.39%
SGHT - APYX
28%
Poorly correlated
+1.58%
ITOC - APYX
26%
Poorly correlated
+8.46%
CLPT - APYX
25%
Poorly correlated
+4.56%
EMBC - APYX
25%
Poorly correlated
+1.56%
A - APYX
25%
Poorly correlated
-0.52%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ACMR52.433.76
+7.73%
ACM Research
BANL2.930.03
+1.03%
CBL International Limited
AREC1.08-0.01
-0.46%
American Resources Corp
IP34.66-0.47
-1.34%
International Paper Co
RMIX8.39-0.23
-2.67%
Suncrete Inc.